NANJING, China, 11 de noviembre de 2025/PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) anunció que la proteína de fusión IL-2 mu-Fc (IL-2 mu-Fc), SIM0278, dirigida a células T reguladoras (Treg), ha entrado oficialmente en un estudio clínico de fase II en China para el tratamiento...
Hence then, the article about la proteina de fusion mutante il 2 de simcere sim0278 entro en fase ii de ensayos clinicos was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( La proteína de fusión mutante IL-2 de Simcere, SIM0278, entró en fase II de ensayos clínicos )
Also on site :
- This 30-Year-Old Start to a Book Series Is Named the Best Epic Fantasy on Goodreads
- New Study Claims That Traveling Regularly Can Actually Help You Live Longer
- PIN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Pinterest, Inc.